Ignite Creation Date:
2024-05-06 @ 1:14 AM
Last Modification Date:
2024-10-26 @ 11:01 AM
Study NCT ID:
NCT01767129
Status:
COMPLETED
Last Update Posted:
2022-04-29
First Post:
2013-01-09
Brief Title:
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinsons Disease Patients
Sponsor:
Avanir Pharmaceuticals
Organization:
Avanir Pharmaceuticals
Study Overview
Official Title:
A Phase 2a Double-blind Randomized Placebo-controlled Crossover Study to Evaluate the Safety and Efficacy of AVP-923 DextromethorphanQuinidine in the Treatment of Levodopa-induced Dyskinesia in Parkinsons Disease Patients
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LID in PD
Brief Summary:
To evaluate the efficacy safety and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine AVP-923-45 compared to placebo for the treatment of levodopa-induced dyskinesia LID in patients with Parkinsons disease PD
Detailed Description:
Proof-of-concept phase 2a double-blind randomized placebo-controlled crossover study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None